Pfizer's $43 billion acquisition of Seagen, a biotechnology company specializing in cancer treatments, is aimed at expanding Pfizer's market in oncology. This is a needle-sharp case of problem reaction solution. The exposure of the medical industry is going to be the hardest pill for people of the world to swallow.
Pfizer's $43 billion acquisition of Seagen, a biotechnology company specializing in cancer treatments, is aimed at expanding Pfizer's market in oncology. This is a needle-sharp case of problem reaction solution. The exposure of the medical industry is going to be the hardest pill for people of the world to swallow.
More like problem creation solution.